# Selinexor, Cyclophosphamide and Prednisone in Myeloma

> **NCT06212596** · PHASE2 · COMPLETED · sponsor: **University of Leeds** · enrollment: 66 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06212596
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-16
- **Primary completion:** 2022-10-25
- **Final completion:** 2023-11-14
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212596, "Selinexor, Cyclophosphamide and Prednisone in Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06212596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*